<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682471-A1" country="EP" doc-number="2682471" kind="A1" date="20140108" family-id="35785733" file-reference-id="311103" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146585819" ucid="EP-2682471-A1"><document-id><country>EP</country><doc-number>2682471</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13187050-A" is-representative="NO"><document-id mxw-id="PAPP154848011" load-source="docdb" format="epo"><country>EP</country><doc-number>13187050</doc-number><kind>A</kind><date>20050620</date><lang>EN</lang></document-id><document-id mxw-id="PAPP191080971" load-source="docdb" format="original"><country>EP</country><doc-number>13187050.3</doc-number><date>20050620</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140556658" ucid="EP-05761074-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>05761074</doc-number><kind>A</kind><date>20050620</date></document-id></priority-claim><priority-claim mxw-id="PPC140555028" ucid="EP-11151437-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>11151437</doc-number><kind>A</kind><date>20050620</date></document-id></priority-claim><priority-claim mxw-id="PPC140556410" ucid="US-58073004-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>58073004</doc-number><kind>P</kind><date>20040621</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1877551018" load-source="docdb">C12P  19/04        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551019" load-source="docdb">C12N  15/55        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551020" load-source="docdb">C12N   9/24        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551021" load-source="docdb">C12N   9/16        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551022" load-source="docdb">C08B  37/00        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551023" load-source="docdb">A23L  29/269       20160101AFI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1877551024" load-source="docdb">C12N  15/56        20060101ALI20161107BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989634713" load-source="docdb">C07G  99/00        20090101AFI20081227RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1913142479" load-source="docdb" scheme="CPC">C08L   5/00        20130101 FI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1913147623" load-source="docdb" scheme="CPC">A23L  29/272       20160801 LI20160801BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996927285" load-source="docdb" scheme="CPC">C12N   9/2405      20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996927589" load-source="docdb" scheme="CPC">C12Y 302/01031     20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996929111" load-source="docdb" scheme="CPC">C12P  19/04        20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996930404" load-source="docdb" scheme="CPC">C12N   9/2402      20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996930607" load-source="docdb" scheme="CPC">C12N   9/16        20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996931160" load-source="docdb" scheme="CPC">C08B  37/006       20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996932325" load-source="docdb" scheme="CPC">A23C   9/137       20130101 LI20151127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1996935566" load-source="docdb" scheme="CPC">A23C   9/1544      20130101 LI20151127BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132362090" lang="DE" load-source="patent-office">Genetisch aufbereitetes Gelan</invention-title><invention-title mxw-id="PT132362091" lang="EN" load-source="patent-office">Genetically purified gellan gum</invention-title><invention-title mxw-id="PT132362092" lang="FR" load-source="patent-office">Gomme gellane génétiquement purifiée</invention-title><citations><patent-citations><patcit mxw-id="PCIT242945122" load-source="docdb" ucid="US-6663911-B2"><document-id format="epo"><country>US</country><doc-number>6663911</doc-number><kind>B2</kind><date>20031216</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945123" load-source="docdb" ucid="WO-2001064897-A2"><document-id format="epo"><country>WO</country><doc-number>2001064897</doc-number><kind>A2</kind><date>20010907</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>"In Vitro Mutagenesis Protocols", 2002, HUMANA PRESS</text><sources><source mxw-id="PNPL58299652" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BEIL S ET AL: "Purification and characterization of the arylsulfatase synthesized by Pseudomonas aeruginosa PAO during growth in sulfate-free medium and cloning of the arylsulfatase gene (atsA).", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS 15 APR 1995, vol. 229, no. 2, 15 April 1995 (1995-04-15), pages 385 - 394, XP002492168, ISSN: 0014-2956</text><sources><source mxw-id="PNPL58299653" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>HARDING N E ET AL: "Organization of genes required for gellan polysaccharide biosynthesis in S. elodea ATCC 31461", JOURNAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY, BASINGSTOKE, GB, vol. 31, no. 2, 1 January 2004 (2004-01-01), pages 70 - 82, XP008083483, ISSN: 1367-5435</text><sources><source mxw-id="PNPL58299654" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>ISHIKAWA; HOTTA: "FramePlot: a new implementation of the Frame analysis for predicting protein-coding regions in bacterial DNA with a high G+C content", FEMS MICROBIOLOGY LETTERS, vol. 174, 1999, pages 251 - 253</text><sources><source mxw-id="PNPL58299655" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIM ET AL., APPL MICROBIOL BIOTECHNOL., vol. 63, no. 5, February 2004 (2004-02-01), pages 553 - 9</text><sources><source mxw-id="PNPL58299656" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIM J-H ET AL: "Purification and characterization of arylsulfatase from Sphingomonas sp. AS6330.", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY FEB 2004, vol. 63, no. 5, February 2004 (2004-02-01), pages 553 - 559, XP002492167, ISSN: 0175-7598</text><sources><source mxw-id="PNPL58299657" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>LENZ, O.; E. SCHWARTZ; J. DERNEDDE; M. EITINGER; B. FRIEDRICH: "The Alcaligenes eutrophus H16 hoxX gene participates in hydrogenase regulation", J BACTERIOL., vol. 176, 1994, pages 4385 - 4393</text><sources><source mxw-id="PNPL58299658" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>R. W. OLD; S. B. PRIMROSE: "Principles of Gene Manipulation: An Introduction to Genetic Engineering", 1994, BLACKWELL PUBLISHING</text><sources><source mxw-id="PNPL58299659" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13187050-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13187050</doc-number><kind>A</kind><date>20050620</date></document-id></child-doc><parent-doc ucid="EP-05761074.3"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05761074.3</doc-number><date>20050620</date></document-id><parent-grant-document ucid="EP-1766601-B1"><document-id><country>EP</country><doc-number>1766601</doc-number><kind>B1</kind><date>20131002</date></document-id></parent-grant-document></parent-doc></relation><relation type="division"><child-doc ucid="EP-13187050-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13187050</doc-number><kind>A</kind><date>20050620</date></document-id></child-doc><parent-doc ucid="EP-11151437.8"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>11151437.8</doc-number><date>20110119</date></document-id><parent-grant-document ucid="EP-2325324-B1"><document-id><country>EP</country><doc-number>2325324</doc-number><kind>B1</kind><date>20141022</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919520704" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CP KELCO US INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919522758" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CP KELCO U.S., INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR919014493" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CP Kelco U.S., Inc.</last-name><iid>101408529</iid><address><street>3100 Cumberland Boulevard, Suite 600</street><city>Atlanta, GA 30339</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919516755" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CLEARY JOSEPH M</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919511746" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CLEARY, JOSEPH M.</last-name></addressbook></inventor><inventor mxw-id="PPAR919019711" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CLEARY, JOSEPH M.</last-name><address><street>7078 Primentel Lane</street><city>Carlsbad, CA 92009-6612</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919517280" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>COLEMAN RUSSELL J</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919533861" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>COLEMAN, RUSSELL J.</last-name></addressbook></inventor><inventor mxw-id="PPAR919016847" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>COLEMAN, RUSSELL J.</last-name><address><street>11042 W. Ocean Air Drive 343</street><city>San Diego, CA 92130</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919532246" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>HARDING NANCY E</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919509929" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>HARDING, NANCY E.</last-name></addressbook></inventor><inventor mxw-id="PPAR919015464" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>HARDING, NANCY E.</last-name><address><street>9028 Ellingham Street</street><city>San Diego, CA 92129</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919526000" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>PATEL YAMINI N</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919532622" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>PATEL, YAMINI N.</last-name></addressbook></inventor><inventor mxw-id="PPAR919013621" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>PATEL, YAMINI N.</last-name><address><street>12258 Oakview Way</street><city>San Diego, CA 92128</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919015595" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kiernan, Lisa</last-name><suffix>et al</suffix><iid>101407941</iid><address><street>Murgitroyd &amp; Company Scotland House 165-169 Scotland Street</street><city>Glasgow G5 8PL</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549757806" load-source="docdb">AT</country><country mxw-id="DS549752605" load-source="docdb">BE</country><country mxw-id="DS549829768" load-source="docdb">BG</country><country mxw-id="DS549824561" load-source="docdb">CH</country><country mxw-id="DS549911939" load-source="docdb">CY</country><country mxw-id="DS549757807" load-source="docdb">CZ</country><country mxw-id="DS549752606" load-source="docdb">DE</country><country mxw-id="DS549911940" load-source="docdb">DK</country><country mxw-id="DS549911941" load-source="docdb">EE</country><country mxw-id="DS549830226" load-source="docdb">ES</country><country mxw-id="DS549753592" load-source="docdb">FI</country><country mxw-id="DS549829769" load-source="docdb">FR</country><country mxw-id="DS549752607" load-source="docdb">GB</country><country mxw-id="DS549911942" load-source="docdb">GR</country><country mxw-id="DS549757808" load-source="docdb">HU</country><country mxw-id="DS549824566" load-source="docdb">IE</country><country mxw-id="DS549911943" load-source="docdb">IS</country><country mxw-id="DS549829790" load-source="docdb">IT</country><country mxw-id="DS549911944" load-source="docdb">LI</country><country mxw-id="DS549753601" load-source="docdb">LT</country><country mxw-id="DS549838838" load-source="docdb">LU</country><country mxw-id="DS549753602" load-source="docdb">MC</country><country mxw-id="DS549830227" load-source="docdb">NL</country><country mxw-id="DS549838839" load-source="docdb">PL</country><country mxw-id="DS549824567" load-source="docdb">PT</country><country mxw-id="DS549830228" load-source="docdb">RO</country><country mxw-id="DS549838840" load-source="docdb">SE</country><country mxw-id="DS549752608" load-source="docdb">SI</country><country mxw-id="DS549829791" load-source="docdb">SK</country><country mxw-id="DS549911945" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128673873" lang="EN" load-source="patent-office"><p id="pa01" num="0001">Mutational inactivation of proteins involved in para-cresol production in certain milk products results in improved taste and odour. The undesirable para-cresol forms over time as a result of enzymes produced by the bacterium that produces gellan gum. Since the gellan is typically used in a relatively unpurified form, the enzymes are added to the milk along with the gellan. Inactivation of the enzymes is a genetic means of eliminating the enzymes without requiring any additional purification or processing.
<img id="iaf01" file="imgaf001.tif" wi="152" he="69" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA128738153" lang="EN" source="EPO" load-source="docdb"><p>Mutational inactivation of proteins involved in para-cresol production in certain milk products results in improved taste and odour. The undesirable para-cresol forms over time as a result of enzymes produced by the bacterium that produces gellan gum. Since the gellan is typically used in a relatively unpurified form, the enzymes are added to the milk along with the gellan. Inactivation of the enzymes is a genetic means of eliminating the enzymes without requiring any additional purification or processing.</p></abstract><description mxw-id="PDES63959861" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.</p><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0002" num="0002">The invention relates to the field of food additives. In particular it relates to the field of dairy food additives. More particularly it relates to additives to sterilized milk products.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0003" num="0003">Gellan gum is an extracellular polysaccharide produced by the bacteria <i>Sphingomonas elodea.</i> Gellan gum produced by S. <i>elodea</i> is commercially available as Kelcogel LT100<sup>®</sup> from CP Kelco, San Diego, CA. Commercially, gellan gum is formed by aerobic fermentation. Upon completion of fermentation, the broth is pasteurized to kill viable cells prior to recovery of the gum from the fermentation broth.</p><p id="p0004" num="0004">Gellan gum comprises the sugars glucose, glucuronic acid, and rhamnose in a 2:1:1 molar ratio, which are linked to form a tetrasaccharide repeat unit. Native gellan gum is acetylated and glycerylated on the same glucose residues. On average, there is one acetyl group and one half glyceryl group per tetrasaccharide repeat unit.</p><p id="p0005" num="0005">The method of recovery of the gellan gum affects the characteristics of the gum. Direct recovery yields a soft, flexible gel. Gellan gum has long been used in cultured, retorted, and frozen dairy products due to its textural and rheological properties.<!-- EPO <DP n="2"> --> However, an off-flavor and odor develop in otherwise shelf-stable, milk-based, gellan-containing products; this flavor and odor render the foods unpalatable. The off-flavor and odor have been linked to the formation of para-cresol from substrates in milk, <i>e.g.,</i> para-cresyl sulfate and para-cresyl glucouronide. Para-cresol is detectable in milk-based, gellan-containing products that have been treated at ultra high temperatures and stored at room temperature.</p><p id="p0006" num="0006">In an effort to eliminate this problem, gellan has been deacylated with hot alkali treatment. While effective in eliminating the para-cresol, the deacylation processing makes the gellan gum more brittle and less useful for certain food applications. Another approach to eliminate this problem is the pre-treatment of native gellan gum with a denaturing agent, such as sodium hypochlorite or potassium hydroxide. This approach adds material and processing costs. There is a need in the art for a gellan product which does not produce para-cresol upon prolonged storage in a sterilized dairy product and which does not require extra processing steps.</p><heading id="h0003">BRIEF SUMMARY OF THE INVENTION</heading><p id="p0007" num="0007">In a first embodiment a composition is provided which comprises gellan gum substantially free of arylsulfatase protein.</p><p id="p0008" num="0008">In a second embodiment a composition is provided which comprises gellan gum substantially free of β-glucuronidase protein.</p><p id="p0009" num="0009">In a third embodiment of the invention a composition is provided which comprises gellan gum substantially free of both arylsulfatase and β-glucuronidase proteins.</p><p id="p0010" num="0010">In a fourth embodiment of the invention a method is provided for producing a gellan gum composition. <i>Sphingomonas elodea</i> is cultured in a culture medium. The <i>Sphingomonas elodea</i> produces no catalytically active arylsulfatase, or no<!-- EPO <DP n="3"> --> catalytically active β-glucuronidase, or no catalytically active arylsulfatase and no catalytically active β-glucuronidase. The culture medium is collected. Gellan gum is precipitated from the culture medium.</p><p id="p0011" num="0011">A microbiologically pure culture of <i>Sphingomonas elodea</i> is provided in a fifth embodiment of the invention. It is arylsulfatase-deficient.</p><p id="p0012" num="0012">Another microbiologically pure culture of <i>Sphingomonas elodea</i> is provided in a sixth embodiment of the invention. It is β-glucuronidase-deficient.</p><p id="p0013" num="0013">Still another embodiment of the invention is a microbiologically pure culture of <i>Sphingomonas elodea.</i> It is deficient in both arylsulfatase and β-glucuronidase.</p><p id="p0014" num="0014">An eighth embodiment of the invention provides an isolated and purified polynucleotide encoding a <i>Sphingomonas elodea</i> arylsulfatase. The arylsulfatase has an amino acid sequence according to SEQ ID NO: 2.</p><p id="p0015" num="0015">A ninth embodiment of the invention provides an isolated and purified polynucleotide encoding a <i>Sphingomonas elodea</i> β-glucuronidase. The β-glucuronidase has an amino acid sequence according to SEQ ID NO: 5.</p><p id="p0016" num="0016">A tenth embodiment of the invention is an isolated and purified polynucleotide comprising <i>Sphingomonas elodea</i> genomic DNA. The genomic DNA comprises a deletion of all or part of its arylsulfatase coding sequence.</p><p id="p0017" num="0017">An eleventh embodiment of the invention is an isolated and purified polynucleotide comprising <i>Sphingomonas elodea</i> genomic DNA. The genomic DNA comprises a deletion of all or part of its β-glucuronidase coding sequence.<!-- EPO <DP n="4"> --></p><p id="p0018" num="0018">These and other embodiments of the invention as described in more detail below provide the art with cost-effective means to make a more consumer-acceptable, sterilized, gellan-containing, dairy product.</p><heading id="h0004">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0019" num="0019"><figref idrefs="f0001">Figure 1</figref>. Genetic map of the genomic region around the arylsulfatase gene (<i>atsA</i>) and location of the regions amplified by PCR and cloned into plasmid pL02. Plasmid pL02 with the cloned PCR fragments was then used to replace this region of the genome with the deletion, by homologous recombination.</p><p id="p0020" num="0020"><figref idrefs="f0002">Figure 2</figref>. Restriction map of the genomic region around the beta-glucuronidase gene (<i>gusA</i>) of <i>Sphingomonas elodea.</i> Positions of transposon insertions in clones BG-6 and BG-7 are indicated at the bottom.</p><heading id="h0005">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p0021" num="0021">The present inventors have found that if either of the genes encoding the enzymes arylsulfatase and β-glucuronidase or both genes are mutationally inactivated in the bacterium <i>Sphingomonas elodea,</i> the bacterium produces a gellan that has superior properties for certain purposes. In particular, the gellan that is produced by such mutants imparts to sterilized milk products a longer shelf-life.</p><p id="p0022" num="0022">If one or both of the enzymes are not inactivated then they produce para-cresol from substrates (p-cresyl-sulfate and p-cresyl-glucuronide) found in the milk. The para-cresol imparts an odor and flavor that is generally unpalatable to consumers. Eliminating these enzymes reduces the rate at which para-cresol is produced in the sterilized milk or milk product on the shelf.</p><p id="p0023" num="0023">Mutations in either or both of the enzymes may be used to reduce the rate of para-cresol production. The mutations are preferably of the type that totally inactivates the<!-- EPO <DP n="5"> --> protein, such as insertions, nonsense, frameshift, or deletion mutations. Any technique known in the art for producing such mutations may be used. The applicants used a transposon insertion strategy to identify the genes encoding arylsulfatase and β-glucuronidase. A deletion mutation in each gene was then constructed by homologous recombination using 5' and 3' DNA fragments flanking the gene which were joined together. Nonetheless, other strategies can be used to obtain the mutations in these genes. The mutations can be made directly in a gellan "production" strain, or the mutations can be transferred to such a strain from a strain in which the mutation is first made. Techniques for site-directed mutagenesis are well known in the art. <i>See, e.g.,</i> "<nplcit id="ncit0001" npl-type="b"><text>In Vitro Mutagenesis Protocols, second edition, Braman, Jeff, ed., Humana Press, 2002</text></nplcit>, and the commercially available QuikChange™ kit (Stratagene). Provided with the wild-type sequences of the S. <i>elodea</i> arylsulfatase and β-glucuronidase genes, one of skill in the art can readily make a variety of desired mutations in these genes.</p><p id="p0024" num="0024">The sequence of the wild-type and mutant genes encoding arylsulfatase and β-glucuronidase have been determined. See SEQ ID NO: 1 (wild-type arylsulfatase), SEQ ID NO: 3 (deletion of arylsulfatase), SEQ ID NO: 4 (wild-type β-glucuronidase), and SEQ ID NO: 6 (deletion of β-glucuronidase). The identification of these genes and their nucleotide sequences permits one of skill in the art to readily make other mutations having the desired null phenotype for expression of these enzymes. Mutations such as insertions, deletions, nonsense, and frameshift are most likely to result in a null phenotype for the enzymes. Missense mutations can also be made and routinely tested for their effect on enzyme activity. Standard techniques of microbial genetics can be used to make suitable mutations. See, <i>e.g.,</i> <nplcit id="ncit0002" npl-type="b"><text>Principles of Gene Manipulation: An Introduction to Genetic Engineering, R. W. Old, S. B. Primrose, Blackwell Publishing, 1994</text></nplcit>. Standard enzyme assays can<!-- EPO <DP n="6"> --> be used to test for loss of activity of the mutated enzymes. See, <i>e.g.,</i> <nplcit id="ncit0003" npl-type="s"><text>Kim et al., Appl Microbiol Biotechnol. 2004 Feb; 63(5):553-9</text></nplcit>.</p><p id="p0025" num="0025">Compositions of the present invention which are substantially free of arylsulfatase or β-glucuronidase contain less than 95%, 96%, 97%, 98%, or 99% of the amount of the particular protein than is contained in wild-type strains. Such a reduction in amount of enzyme should lead to sterilized milk compositions which have less than 90 %, 93 %, 95 %, 97 %, or 99 % of the amount of para-cresol that is produced in compositions containing gellan from wild-type strains. The amount of arylsulfatase or β-glucuronidase protein which is produced can be measured by enzyme assay using a readily assayable substrate such as 5-bromo-4-chloro-3-indolyl sulfate (X-SO4); CAS No. 6578-07-0 from Sigma or using 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-GlcA); CAS No. 114162-64-0, from Sigma or RPI Corp. or using p-nitrocatechol. Alternatively the protein can be measured using an immunological technique such as a Western blot.</p><p id="p0026" num="0026">Gellan gum is typically used in sterilized or ultra high temperature (UHT) treated dairy products or frozen dairy products. Such products include without limitation, ice cream, frozen yogurt, pudding, whipped dairy product, coffee creamer, crème brulee, and dairy beverages. The gellan gum of the present invention can be used in these or any other foods as can typical gellan from a wild-type strain. Gellan gum is typically used for suspension of fine particles, but it also can be used to impart a favorable mouth feel.</p><p id="p0027" num="0027">Gellan gum can be produced using the mutant strains of the present invention according to any of the methods known in the art for wild-type strains. The bacteria are typically grown in a liquid culture medium. Such medium typically contains a carbon source, phosphate, organic and inorganic nitrogen sources, and appropriate trace elements. The fermentation is typically conducted under sterile conditions, with<!-- EPO <DP n="7"> --> aeration and agitation. At the end of the fermentation period, the culture medium is collected, typically without removing the cells. The fermentation broth can be pasteurized to kill viable cells prior to recovery of the gellan gum. The gellan gum can be precipitated as is known in the art. Typically this is done with an alcohol, such as isopropanol. The precipitated gellan can be dried prior to rehydration.</p><p id="p0028" num="0028">Para-cresol can be measured by any means known in the art. One method which can be used employs dichloromethane extraction, concentration, and gas chromatographic-mass spectroscopy.</p><p id="p0029" num="0029">While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.</p><heading id="h0006">EXAMPLES</heading><heading id="h0007">Example 1</heading><p id="p0030" num="0030">The following reagents were used in screening and characterizing mutant strains:
<ul><li>5-bromo-4-chloro-3-indolyl sulfate (X-SO<sub>4</sub>); CAS No. 6578-07-0 Source: Sigma.</li><li>5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-GlcA); CAS No. 114162-64-0, Source: Sigma or RPI Corp.</li></ul></p><heading id="h0008">Example 2</heading><p id="p0031" num="0031">The genes encoding arylsulfatase and β-glucuronidase were identified by making a library of random transposon mutants in a nonmucoid strain of <i>S. elodea,</i> Gps2, using<!-- EPO <DP n="8"> --> the commercially available EZ::TN™ &lt;R6Kgamma-ori /KAN-2&gt; insertion kit from Epicentre (Madison, WI). Kanamycin resistant mutant strains were screened for lack of (or significantly reduced) blue color on selective media with specific chromogenic substrates. See Example 1. Mutants blocking arylsulfatase production or activity were identified using the chromogen 5-bromo-4-chloro-3-indolyl sulfate (X-S04) on agar with a defined medium with chloride salts. Mutants of β-glucuronidase were selected on a defined medium with the chromogen 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-GlcA).</p><p id="p0032" num="0032">The transposon and adjacent genomic DNA were subsequently excised from the chromosome using restriction enzymes. The restriction enzyme fragments were circularized with ligase and transformed into <i>Escherichia coli</i> where the transposon-containing DNA can replicate due to presence of a replicon in the transposon. Plasmid DNA was purified and sequenced. The plasmid with the gene for arylsulfatase was designated R6K-AS#14E. A portion of this plasmid has been sequenced (SEQ ID NO: 1). The plasmid with the gene for beta-glucuronidase was designated R6K-BG#6S. A portion of this plasmid has been sequenced (SEQ ID NO: 4.) These plasmids in <i>Escherichia coli</i> strain EC100D pir+ are being deposited at the American Type Culture Collection, Manassas, VA, on June 21, 2004.</p><p id="p0033" num="0033">In the bacterium that had an inactivated arylsulfatase, the transposon had actually inserted in a gene for a hypothetical protein that was adjacent to the gene for arylsulfatase. In the bacterium that had an inactivated β-glucuronidase, the transposon insertion was located in the amino portion of the gene for β-glucuronidase. DNA sequencing of the genes showed that they were homologous to known genes from other species in the database of the National Center for Biotechnology Information (NCBI).<!-- EPO <DP n="9"> --></p><p id="p0034" num="0034">The genes for arylsulfatase and β-glucuronidase and adjacent genomic DNA were sequenced. Deletions of the genes were constructed on a plasmid and then transferred into S. <i>elodea</i> strains S-60wtc and PDG-1. See <patcit id="pcit0001" dnum="WO0164897A"><text>WO 01/64897</text></patcit>. The deletions were inserted in the genome by homologous recombination. DNA sequences flanking the target gene were amplified by PCR and cloned into the plasmid vector pL02. (<nplcit id="ncit0004" npl-type="s"><text>Lenz, O., E. Schwartz, J. Dernedde, M. Eitinger and B. Friedrich. 1994, "The Alcaligenes eutrophus H16 hoxX gene participates in hydrogenase regulation," J. Bacteriol. 176:4385-4393</text></nplcit>.) This construct was transferred into the S. <i>elodea</i> strain by conjugation. The resulting kanamycin resistant strains were then grown for 30-40 generations in the absence of antibiotic. Isolates that had lost the plasmid were detected by selection for sucrose tolerance due to loss of the <i>sacB</i> gene on pL02, and confirmed by kanamycin sensitivity. Isolates that had lost the plasmid after the non-selective growth were of two types, deletion or wild-type. The desired deletion strains were identified by lack of blue color on appropriate indicator agar (see example 1) and by diagnostic PCR. The scheme for construction is shown in <figref idrefs="f0001">Figure 1</figref> below.</p><p id="p0035" num="0035">To construct a precise deletion of the gene (<i>atsA</i>) for arylsulfatase it was necessary to determine the most likely start codon for the <i>atsA</i> gene and the start and stop codons of the adjacent genes. The locations of the ends of the genes were determined based on DNA sequences, homologies to other genes in GenBank and third base GC preference using the FramePlot-3 program. <nplcit id="ncit0005" npl-type="s"><text>Ishikawa and Hotta. "FramePlot: a new implementation of the Frame analysis for predicting protein-coding regions in bacterial DNA with a high G+C content." FEMS Microbiology Letters 174:251-253 (1999</text></nplcit>). This analysis indicated that the arylsulfatase gene is translationally coupled to the gene for the conserved hypothetical protein, <i>i.e.,</i> the stop codon of the arylsulfatase gene overlaps with the start codon of the gene for the conserved<!-- EPO <DP n="10"> --> hypothetical protein. The arylsulfatase deletion was constructed to leave the alkylsulfatase gene and the gene for the unknown protein intact, since it is not known whether these proteins are required for optimal cell growth and gellan production.</p><p id="p0036" num="0036">PCR primers AS5 (CC<u>GAGCTC</u>AACGCCTTCGACTATGTCCA; SEQ ID NO: 11) and AS6 (CC<u>TCTAGA</u>CTGGGGATTGTCCGGAAAAG; SEQ ID NO: 12) were used to amplify a 512 bp fragment just upstream of the start codon of <i>atsA</i> as a <i>Sac</i>I-<i>Xba</i>I fragment (total 528 bp). Primers AS3 (CG<u>TCTAGA</u>TCCACCCCGGCGACCTTCCC; SEQ ID NO: 13) and AS4 (TATA<u>GCATGC</u>GGCGACCACGGGCTCCTCCTCA; SEQ ID NO: 14) were used to amplify a 479 bp fragment including the end of the <i>atsA</i> gene and the start of the conserved hypothetical protein as an <i>Xba</i>I<i>-Sph</i>I fragment (total 497 bp). Thus, the stop codon of <i>atsA</i> was retained but the start codon was deleted, so no portion of the arylsulfatase protein should be synthesized. Restriction sites for cloning were added to the ends of the primers. The PCR fragments were ligated sequentially into the polylinker of plasmid vector pL02, to form the deletion of the <i>atsA</i> gene. The upstream <i>Sae</i>I-<i>Xba</i>I fragment was cloned into <i>Sac</i>I-<i>Xba</i>I cut pL02. Subsequently the downstream <i>Xba</i>I<i>-Sph</i>I fragment was cloned (<figref idrefs="f0002">Figure 2</figref>). This plasmid with deletion of the <i>atsA</i> gene was transferred by conjugation into S. <i>elodea</i> strains S60wtc and PDG-1 to allow recombination of the plasmid into the chromosome. Kanamycin resistant isolates were purified, then grown in the absence of antibiotic and plated on medium with sucrose and X-SO<sub>4</sub> to select isolates with sucrose tolerance due to loss of the plasmid-encoded <i>sacB</i> gene. Sucrose resistance, kanamycin sensitive, yellow colonies were selected. The <i>atsA</i> derivatives of S60wtc and PDG-1 were designated GAS-1 and PAS-1 respectively.</p><p id="p0037" num="0037">A deletion of the gene (<i>gusA</i>) for β-glucuronidase was constructed on plasmid pL02 and transferred into S60wtc, GAS-1. The most likely start codon for the <i>gusA</i> gene was determined by homology to other proteins and the presence of ribosome binding<!-- EPO <DP n="11"> --> sites. A region of secondary structure is upstream of the start codon. The deletion of the <i>gusA</i> gene was constructed to maintain secondary structures upstream and downstream of <i>gusA.</i> Primers Bgluc3 (AA<u>CTGCAG</u>ACACGTGGCTTGTGCCGAAC; SEQ ID NO: 7) and Bgluc4 (GGC<u>TCTAGA</u>CTTCTCCCTGTTCCTCCGGGAAA; SEQ ID NO: 8) were used to amplify a 560 bp fragment upstream of the <i>gusA</i> gene as a <i>Pst</i>I<i>-Xba</i>I fragment (total 577 bp). Primers Bgluc1 (TT<u>TCTAGA</u>TGACTGTCCAGGCCCCTCTC; SEQ ID NO: 9) and Bgluc2 (TC<u>GAGCTC</u>CAATGTCCTCGTAGCTGTTC; SEQ ID NO: 10) were used to amplify a 489 bp fragment downstream of <i>gusA</i> as an <i>Xba</i>I<i>-Sac</i>I fragment (total 505 bp). The <i>Pst</i>I<i>-Xba</i>I fragment was cloned into <i>Pst</i>I<i>-Xba</i>I cut pLO2. Subsequently the downstream <i>Xba</i>I-<i>Sac</i>I fragment was cloned. This plasmid with deletion of the <i>gusA</i> gene was transferred by conjugation into S. <i>elodea</i> strains S60wtc, GAS-1 and PAS-1 to allow recombination. Kanamycin resistant isolates were purified, grown in the absence of antibiotic and then plated on media with sucrose and X-GlcA to select isolates with sucrose tolerance due to loss of the plasmid-encoded <i>sacB</i> gene. A mixture of blue-green (wild-type) and light green (mutant) colonies was obtained. Sucrose resistant, light green isolates were confirmed for plasmid loss by kanamycin sensitivity. The <i>gusA</i> deletion derivatives of S60wtc, GAS-1 and PAS-1 were designated GBG, GBAD and PBAD respectively.</p><p id="p0038" num="0038">The deletion of the gene (<i>atsA</i>) for arylsulfatase in strains S60wtc and PDG-1 has been completed. The gene for β-glucuronidase has been identified and sequenced. The adjacent DNA was sequenced. A deletion of the gene for β-glucuronidase has also been constructed in each of 560, PDG-1, and GAS-1.</p><p id="p0039" num="0039">Samples of gellan made from strains GAS-1 (with a deletion of the gene for arylsulfatase) and GBAD-1 (with deletions of genes for both arylsulfatase and β-glucuronidase) were evaluated for p-cresol production at monthly intervals in an ultrahigh temperature dairy application test. Gellan samples from the wild-type strain<!-- EPO <DP n="12"> --> produced 3 to 152 (average 65) ppb p-cresol after one month and 4 to 212 (average 96) ppb p-cresol after two months. Samples of gellan from GAS-1 produced about 1 to 3 ppb p-cresol after one to five months. Samples of gellan from GBAD-1 produced less than 1 ppb (limit of detection) when tested for up to three months.
<ul><li>A. A composition comprising gellan gum substantially free of arylsulfatase protein.</li><li>B. A composition comprising gellan gum substantially free of β-glucuronidase protein.</li><li>C. A composition comprising gellan gum substantially free of arylsulfatase and β-glucuronidase proteins.</li><li>D. The composition of any of clauses A to C which is a culture broth of <i>Sphingomonas elodea.</i></li><li>E. The composition of any of clauses A to C which is a precipitated culture broth of <i>Sphingomonas elodea.</i></li><li>F. The composition of any of clauses A to C which is a sterilized milk product.</li><li>G. An isolated and purified polynucleotide encoding a <i>Sphingomonas elodea</i> arylsulfatase having an amino acid sequence according to SEQ ID NO: 2.</li><li>H. The isolated and purified polynucleotide according to clause G which comprises a nucleotide sequence according to nucleotides 521 to 2176 of SEQ ID NO: 1. I. An isolated and purified polynucleotide comprising <i>Sphingomonas elodea</i> genomic DNA with a deletion of all or part of its arylsulfatase coding sequence.</li><li>J. The isolated and purified polynucleotide of clause I wherein the genomic DNA comprises all or part of <i>Sphingomonas elodea</i> genomic DNA encoding alkylsulfatase.</li><li>K. An isolated and purified polynucleotide comprising <i>Sphingomonas elodea</i> genomic DNA with a deletion of all or part of its β-glucuronidase coding sequence.</li><li>L. The isolated and purified polynucleotide of clause K wherein the deletion is of nucleotides 1588 to 3447 SEQ ID NO: 4.</li><li>M. The isolated and purified polynucleotide of clause K wherein the genomic DNA comprises all of part of <i>Sphingomonas elodea</i> genomic DNA encoding conserved hypothetical protein upstream of β-glucuronidase.</li><li>N. The isolated and purified polynucleotide of clause K wherein the genomic DNA comprises all of part of <i>Sphingomonas elodea</i> genomic DNA encoding malate dehydrogenase.</li></ul><!-- EPO <DP n="13"> -->
<img id="ib0001" file="imgb0001.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="14"> -->
<img id="ib0002" file="imgb0002.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="15"> -->
<img id="ib0003" file="imgb0003.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="16"> -->
<img id="ib0004" file="imgb0004.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="17"> -->
<img id="ib0005" file="imgb0005.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="18"> -->
<img id="ib0006" file="imgb0006.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="19"> -->
<img id="ib0007" file="imgb0007.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="20"> -->
<img id="ib0008" file="imgb0008.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="21"> -->
<img id="ib0009" file="imgb0009.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="22"> -->
<img id="ib0010" file="imgb0010.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="23"> -->
<img id="ib0011" file="imgb0011.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="24"> -->
<img id="ib0012" file="imgb0012.tif" wi="157" he="148" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56982914" lang="EN" load-source="patent-office"><!-- EPO <DP n="25"> --><claim id="c-en-0001" num="0001"><claim-text>An isolated and purified polynucleotide comprising <i>Sphingomonas elodea</i> genomic DNA with an inactivating deletion in its arylsulfatase coding sequence, said arylsulfatase coding sequence according to SEQ ID NO: 1.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The isolated and purified polynucleotide of claim 1 encoding a null phenotype <i>Sphingomonas elodea</i> arylsulfatase having an amino acid sequence according to SEQ ID NO: 2.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The isolated and purified polynucleotide of claims 1 or 2, further comprising <i>Sphingomonas elodea</i> genomic DNA with an inactivating deletion in its β-glucuronidase coding sequence, said β-glucuronidase coding sequence according to SEQ ID NO 4.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The isolated and purified polynucleotide of claim 3 wherein the deletion is of nucleotides 1588 to 3447 of SEQ ID NO: 4.</claim-text></claim></claims><drawings mxw-id="PDW16671230" load-source="patent-office"><!-- EPO <DP n="26"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="152" he="79" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="27"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="152" he="213" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="162" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="165" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="162" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
